A medicine safety letter highlights the risk of acute kidney injury in patients treated with fluoroquinolones concomitantly with ace-inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).
Times Live reported on a case of a doctor reporting an ad to the Advertising Regulatory Board. They can only rule on whether advertising is misleading or not and this is where SAHPRA comes in.
Jackie, one of our knowledgeable pharmacists, has been published in BMC Infectious Diseases. She and her co-authors evaluated spontaneously reported cases of ADRs to bedaquiline.